Delcath Systems' (DCTH) Buy Rating Reaffirmed at Canaccord Genuity Group

Key Points

• Analysts at Canaccord Genuity Group have reaffirmed a "buy" rating for Delcath Systems (DCTH) with a price target of $21.00, suggesting an 82.45% potential upside from the current stock price.
• Delcath Systems has a consensus rating of "Moderate Buy" with a price target of $24.00, though recent ratings from other firms range from "hold" to "buy" with varying price targets.
• Delcath Systems reported a $0.07 EPS for the most recent quarter, exceeding estimates and indicating a strong revenue performance of $24.16 million compared to expectations.

Delcath Systems (NASDAQ:DCTH - Get Free Report)'s stock had its "buy" rating restated by analysts at Canaccord Genuity Group in a note issued to investors on Tuesday,Benzinga reports. They presently have a $21.00 price objective on the stock. Canaccord Genuity Group's price objective indicates a potential upside of 82.45% from the stock's current price.

DCTH has been the topic of several other research reports. Wall Street Zen lowered shares of Delcath Systems from a "buy" rating to a "hold" rating in a report on Sunday, October 12th. Craig Hallum reissued a "buy" rating and set a $20.00 price target on shares of Delcath Systems in a research report on Tuesday. HC Wainwright set a $30.00 price target on shares of Delcath Systems and gave the company a "buy" rating in a research report on Monday. Stephens reissued an "overweight" rating and set a $25.00 price target on shares of Delcath Systems in a research report on Monday, June 23rd. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Delcath Systems in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Delcath Systems has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Delcath Systems Stock Performance

Shares of DCTH stock traded up $0.09 on Tuesday, hitting $11.51. 556,082 shares of the company's stock traded hands, compared to its average volume of 609,565. Delcath Systems has a one year low of $8.87 and a one year high of $18.23. The company's fifty day simple moving average is $11.04 and its 200 day simple moving average is $12.41. The stock has a market capitalization of $402.62 million, a price-to-earnings ratio of 230.20 and a beta of 0.84.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.02 by $0.05. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. The company had revenue of $24.16 million for the quarter, compared to analyst estimates of $22.84 million. As a group, sell-side analysts anticipate that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

A number of large investors have recently made changes to their positions in DCTH. USA Financial Formulas bought a new stake in shares of Delcath Systems in the second quarter worth approximately $25,000. California State Teachers Retirement System bought a new stake in shares of Delcath Systems in the second quarter worth approximately $26,000. Tower Research Capital LLC TRC bought a new stake in shares of Delcath Systems in the second quarter worth approximately $40,000. Ameritas Investment Partners Inc. purchased a new position in shares of Delcath Systems in the second quarter worth approximately $42,000. Finally, Legal & General Group Plc purchased a new position in shares of Delcath Systems in the second quarter worth approximately $46,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.